Sales & Marketing

Christopher Savage, managing director, Propensity4, and chief of staff, Inizio Engage, on creating lasting impact over chasing the next opportunity.

Sarah Ghosh, U.S. scientific marketing lead in oncology at Regeneron, discusses developing and adapting the narrative for a medication for every global market.

Overcoming the limits of traditional segmentation through a more connected, responsive and effective approach to health care professional engagement.

Novo's lawsuit claims that Eli Lilly's marketing campaigns for Mounjaro and Zepbound misrepresented the efficacy of Wegovy in comparison.

Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of concentrated AI bets — not scattered pilots — can better drive real transformation without losing sight of governance, culture or patients.

AI-powered data analytics has evolved from a supporting function into the backbone of modern brand strategy and decision-making.

Incyte, Galmed Pharmaceuticals, and Johnson & Johnson each announced acquisitions this week, with deals spanning a $2 billion bet on a Phase III bleeding disorder antibody, a GI medtech pivot, and a $1 billion move into KRAS-targeting degrader conjugates as dealmaking across therapeutic categories continues.

Synchronizing sales and marketing around a unified, customer-centric approach is essential for pharmaceutical companies seeking growth and competitive advantage.

Ken Banta and Andy Milligan explore how life sciences leaders can rebuild relevance, consistency, and trust in today's complex and cost-focused era of healthcare.

Analysis of U.S. drug pricing reform in 2026 highlights how the Inflation Reduction Act, Medicare drug price negotiation, and most-favored-nation pricing initiatives are reshaping pharmaceutical pricing, limiting patent-driven market exclusivity, accelerating generic and biosimilar competition, and driving strategic shifts in market access, pricing models, and innovation priorities across the biopharma industry.

A more thoughtful — and "unified" — model is emerging in consent-driven marketing in pharma.

How organizations can gain an edge in the enterprise transformation to unified analytics that's accelerating across pharma.

Conversational AI is pushing engagers to prioritize clear, explainable guidance as patients and clinicians delegate understanding to chatbots.

Market access strategies are evolving as more biopharma companies commercialize their own therapies, requiring closer alignment with payer requirements, provider education, specialty pharmacy networks, and patient support services to ensure appropriate coverage, prescribing, and long-term adherence.

From data risk to relationship equity, the need to rethink consent in life sciences marketing.

Novo Nordisk is using its first Super Bowl commercial to spotlight an oral formulation of Wegovy that builds on prior approvals of semaglutide, signaling a strategy to expand obesity treatment access beyond injectable GLP-1s.

FDA Commissioner Marty Makary’s warning against mass-marketed copycat drugs escalated the regulatory and legal clash over compounded oral GLP-1 products.

Teva’s VP of US innovative medicines marketing discusses the origins of the company’s new campaign featuring comedian Will Forte.

How pharma marketers can time brand messages to prescribers when it matters most.

As leading drugmakers launch direct-to-patient platforms with steep discounts and digital care bundles, a new channel dynamic is emerging that gives manufacturers greater control of patient engagement while redefining, but not replacing, the strategic role of traditional wholesalers.

The booming obesity drug market is redefining prescriber influence, with nurse practitioners and physician associates emerging as key decision-makers that life sciences marketers can no longer afford to overlook.

“This is about building a powerful bridge between the science that transforms lives and the systems that deliver that transformation,” said Michael J. Hennessy Jr., MJH Life Sciences chairman and CEO, of the BPD Healthcare acquisition.

The importance for pharma in recognizing integrated data sources as necessary infrastructure—not just a competitive edge.

As the pharmaceutical industry moves beyond rule-based omnichannel marketing, a new era of agentic systems is emerging, in which AI-powered agents collaborate with humans to orchestrate engagement, accelerate decision-making, and maintain regulatory compliance in real time.